Glucose Monitoring Shows Dysglycaemia in Premature Infants
In very low birth weight (VLBW) infants, continuous glucose monitoring (CGM) at 36 weeks of postmenstrual age (PMA) revealed subclinical dysglycaemia; male infants showed prolonged hyperglycaemia, and prior insulin therapy predicted extended hypoglycaemia.
METHODOLOGY:
Researchers evaluated the prevalence of dysglycaemia in VLBW infants at 36 weeks of PMA through CGM and investigated associated risk factors.
The prospective cohort included 35 VLBW infants (mean gestational age, 27.3 weeks; 65.7% female infants; mean birth weight, 929 g) who were assessed at 36 weeks from 2016 to 2019.
CGM was performed at 36 weeks of PMA using a blinded Dexcom G4 sensor for 48 hours, with dysglycaemia defined as glucose concentrations > 8 mmol/L (hyperglycaemia) or < 2.6 mmol/L (hypoglycaemia) sustained for at least 30 minutes.
Researchers analysed risk factors (sex and prior insulin therapy) against capillary glucose correlations.
TAKEAWAY:
Overall, dysglycaemia was detected in 68.6% of infants; 28.6% of infants had hyperglycaemia alone, 17.1% had hypoglycaemia alone, and 22.9% had both.
Male sex was linked to a longer duration of hyperglycaemia (B = 252.172; CI, 101.484-402.86; P = .002).
Prior insulin treatment led to an increase in the duration of hypoglycaemia (B = 68.607; CI, 9.932-127.283; P = .023).
Lower birth size and bronchopulmonary dysplasia were also associated with dysglycaemia.
IN PRACTICE:
"Male sex is associated with longer time spent in hyperglycemia and insulin treatment during the admission period is associated with longer time spent in hypoglycemia nearing term age. It is possible that these infants may require more rigorous monitoring of their glucose concentrations even when nearing term age," the authors wrote.
SOURCE:
This study was led by Itay Nilsson Zamir, Department of Clinical Sciences, Pediatrics, Umeå University, Umeå, Sweden. It was published online on June 27, 2025, in the European Journal of Pediatrics.
LIMITATIONS:
The single-centre study design and small sample size may have limited generalisability. The CGM device used (Dexcom G4) had a higher-than-ideal mean absolute relative difference (18.8%). Calibrations relied on point-of-care glucometers rather than on laboratory-analysed values.
DISCLOSURES:
This study was supported by research grants from Umeå University and other sources. The CGM system was donated by Dexcom Inc., which had no role in the study design, data analysis, or publication. The authors declared having no competing interests.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
33 minutes ago
- Yahoo
Breakthrough gene therapy jab reverses hearing loss in weeks
A single jab of a breakthrough gene therapy could reverse hearing loss in people within weeks, according to new research. The cutting-edge therapy improved hearing in children and adults with congenital deafness or severe hearing impairment, with a 7-year-old regaining almost full hearing in a clinical trial, researchers from Sweden's Karolinska Institutet said. The clinical trial, detailed in the journal Nature Medicine, showed that a healthy copy of the OTOF gene injected in the inner ear improved hearing of all 10 participants. The small-scale trial included people who had a genetic form of deafness or severe hearing impairment caused by mutations in a gene called OTOF. These mutations cause a deficiency of the protein otoferlin, which plays a key role in transmitting sound signals from the ear to the brain. While the therapy seemed to work best in children, researchers said, it could benefit adults as well. In the trial, a synthetic, harmless version of the adeno-associated virus was used to deliver a properly functional OTOF gene to the inner ear via a single injection. The effects of the therapy were evident in the majority of patients, whose hearing recovered rapidly after just a month. After six months, researchers noted considerable hearing improvement in all participants, with their average volume of perceptible sound improving from 106 decibels to 52. Those between the ages of five and eight responded best to the treatment, the study found. One seven-year-old girl quickly recovered almost all her hearing, and she was able to hold daily conversations with her mother four months afterwards. 'This is the first time that the method has been tested in teenagers and adults,' Maoli Duan, an author of the study from Karolinska Institutet, said. "Hearing was greatly improved in many of the participants, which can have a profound effect on their life quality. We will now be following these patients to see how lasting the effect is.' Researchers also found that the treatment was safe and well-tolerated. Participants did not report any serious adverse reactions in the follow-up period of 6-12 months. The most common reaction was a reduction in the number of the immune system's neutrophils, a type of white blood cell. "OTOF is just the beginning," Dr Duan said, adding that researchers were working on other common genes behind deafness such as GJB2 and TMC1. 'These are more complicated to treat, but animal studies have so far returned promising results. We are confident that patients with different kinds of genetic deafness will one day be able to receive treatment.'
Yahoo
3 hours ago
- Yahoo
Are these 2 of the best high-yield dividend growth shares to consider today?
I don't think there's a better way for me to source a passive income than by buying UK dividend shares. London's stock market is packed with high-yield income stocks with strong balance sheets and robust market positions, of which many are also reliable dividend growth shares. Here are two such dividend heavyweights I think deserve serious consideration. As you can see, their dividend yields comfortably beat the FTSE 100's prospective average of 3.4%. Dividend stock Dividend growth Dividend yield Primary Health Properties (LSE:PHP) 1.7% 7.2% Tritax Big Box (LSE:BBOX) 4.4% 5.6% Here's why I think they could be among the best dividend shares for investors to consider right now. Under real estate investment trust (REIT) regulations, Primary Health Properties has to pay at least nine-tenths of yearly profits from its rental operations out in dividends. Please note that tax treatment depends on the individual circumstances of each client and may be subject to change in future. The content in this article is provided for information purposes only. It is not intended to be, neither does it constitute, any form of tax advice. This can make REITs more dependable than other UK shares for a large and consistent dividend income. But it doesn't guarantee it, as occupancy and rent collection issues can still strike shareholder returns. However, Primary Health's focus on an ultra-defensive industry greatly reduces such risks. It owns and operates first-contact properties like GP surgeries and community health centres, sites that remain busy at all points of the economic cycle. Furthermore, almost all of its rental agreements are underpinned by NHS and government bodies, providing added stability over time. Don't be mistaken in thinking this sector is just brilliantly boring, however. It also has substantial opportunity for growth under the government's new 10-year Health Plan to '[move] care from hospitals to the community'. Primary Health has grown annual dividends each year since the mid-to-late 1990s. Threats to future growth include future changes to NHS policy and sector oversupply than dents rental rolls. But on balance, I think it's a great stock to consider, and one I hold in my own Stocks and Shares ISA. Tritax Big Box's dividend growth policy isn't quite as impressive as that of its FTSE 250 counterpart. One reason is that it's only been in existence since 2013. Another reason is that the annual dividend fell for the first time during the height of the pandemic five years ago. But this REIT has grown shareholder payouts steadily since then, and is tipped to continue through to 2027 at least. In fact, predicted dividend growth for this year is more than double the rate predicted for the broader UK share complex. Tritax Big Box doesn't operate in defensive sectors, which can leave profits vulnerable during lean periods. But its portfolio composition helps to reduce (if not totally eliminate) the threat to dividends and its share price. It has more than 128 tenants on its books spread across 102 properties. These cover multiple industries and include blue-chip companies like Amazon and Ocado, providing strength through diversification. With online shopping still growing, supply chains being onshored, and data centre demand increasing, I expect demand for its big box assets to rise over time. This could in turn deliver sustained long-term dividend growth. The post Are these 2 of the best high-yield dividend growth shares to consider today? appeared first on The Motley Fool UK. More reading 5 Stocks For Trying To Build Wealth After 50 One Top Growth Stock from the Motley Fool John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Royston Wild has positions in Primary Health Properties Plc and Target Healthcare REIT Plc. The Motley Fool UK has recommended Amazon and Primary Health Properties Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Motley Fool UK 2025
Yahoo
8 hours ago
- Yahoo
Study Finds Simple Change Can Help Manage Blood Sugar
Getting up from the dining table with haste may be the key to managing one's blood sugar, a new study finds. People often experience glucose spikes after eating, particularly when consuming foods high in carbohydrates such as bread, pasta, rice and grains. It's become a known health hack that going on a post-meal walk can help curb sugary spikes caused by such foods. But a study published on Scientific Reports on Wednesday took things even further. The researchers looked into the intricacies of the post-meal walk, particularly with how immediate one has to start walking to receive the most health benefits. The study analyzed a group of 12 people to compare the difference between going on a 10-minute walk right after glucose intake and going on a 30-minute walk a half hour after glucose intake. The findings showed that both methods significantly reduced average blood glucose levels compared to remaining at rest after a meal. However, the 10-minute walk was deemed to be "uniquely effective" at minimizing the peak glucose levels for each individual compared to the delayed 30-minute walk. Participants also rated the 10-minute walk as "significantly easier" than the longer one despite having to start the former with a fuller stomach. It doesn't take a scientist to figure out that last part. Getting a walk in earlier can yield even better results in terms of blood sugar maintenance than putting off a stroll just a little longer. The study suggests that not even tripling the walk duration would give you the same level of benefit. That's a textbook example of when working smart simply beats working Finds Simple Change Can Help Manage Blood Sugar first appeared on Men's Journal on Jul 5, 2025
